Bristol-Myers Squibb
BMY
2,214 hedge funds and large institutions have $100B invested in Bristol-Myers Squibb in 2020 Q3 according to their latest regulatory filings, with 136 funds opening new positions, 890 increasing their positions, 912 reducing their positions, and 91 closing their positions.
49% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 91
1% more funds holding
Funds holding: 2,189 → 2,214 (+25)
1% more capital invested
Capital invested by funds: $98.8B → $100B (+$1.44B)
0.47% less ownership
Funds ownership: 74.52% → 74.06% (-0.47%)
2% less repeat investments, than reductions
Existing positions increased: 890 | Existing positions reduced: 912
9% less call options, than puts
Call options by funds: $1.25B | Put options by funds: $1.38B
15% less funds holding in top 10
Funds holding in top 10: 110 → 93 (-17)
Top Buyers
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$778M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$582M |
| 3 |
Goldman Sachs
New York
|
-$469M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
-$384M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$230M |
BMY Hedge Fund Activity: Q3 2020 in Review
2,214 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2020, worth a combined $100B — up 1.5% from $98.8B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new BMY positions and 91 closed out — a net gain of 45 holders — while 890 added to existing stakes and 912 trimmed.
The largest buyer was Berkshire Hathaway, opening a new position worth an estimated $1.8B. The largest seller was Renaissance Technologies, cutting an estimated $778M.
- 2,214 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2020, up from 2,189 in Q2 2020.
- Funds reported $100B of Bristol-Myers Squibb stock for Q3 2020, up 1.5% quarter-over-quarter.
- 136 funds opened new Bristol-Myers Squibb positions in Q3 2020 and 91 closed out, a net change of +45 holders.
- The largest Bristol-Myers Squibb buyer in Q3 2020 was Berkshire Hathaway, an estimated $1.8B added.
- The largest Bristol-Myers Squibb seller in Q3 2020 was Renaissance Technologies, an estimated $778M sold.
Based on aggregated 13F filings for Q3 2020.